A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia
Klaus H. Metzeler(University Hospital Leipzig), C. D. Bloomfield(Leukemia Research Foundation), Heiko Becker(University of Freiburg), Jason H. Mendler(University of Rochester Medicine), Stefano Volinia(University of Ferrara), Meir Wetzler, Michael A. Caligiuri(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Maria R. Baer(University of Maryland, Baltimore), Jessica Kohlschmidt(The Ohio State University), Guido Marcucci(City of Hope), Sebastian Schwind, Jonathan E. Kolitz(Memorial Sloan Kettering Cancer Center), Thomas H. Carter(University of Iowa), Richard M. Stone(Dana-Farber Cancer Institute), Krzysztof Mrózek(The Ohio State University), A-K Eisfeld(The Ohio State University), Deedra Nicolet(The Ohio State University), Bayard L. Powell(Atrium Health Wake Forest Baptist), A J Carroll(University of Alabama at Birmingham), Susan P. Whitman(The Ohio State University Wexner Medical Center), Y-Z Wu(The Ohio State University), Kati Maharry(Peter MacCallum Cancer Centre)
Cited by 56
Related Papers
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
|Science|1999|11.6k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response
|Proceedings of the National Academy of Sciences|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k